Dar Al Dawa Development & Investment Co. Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JO4101211012
JOD
1.12
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Dar Al Dawa Development & Investment Co. Ltd. stock-summary
stock-summary
Dar Al Dawa Development & Investment Co. Ltd.
Pharmaceuticals & Biotechnology
Dar Al Dawa Development and Investment Company PSC is a Jordan-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical and consumer health products. The Company’s main activities are producing medical, chemical and pharmaceutical products, and importing pharmaceutical products. The Company operates an integrated network of 11 manufacturing facilities spread across Jordan, Middle East and North Africa region, as well as Romania. Its Pharmaceutical Development Unit focuses on the process developing of various dosage forms including tablets, capsules, liquids, dry suspensions, suppositories, creams, ointments, gels, parenterals, ophthalmic and nasal preparations. The Analytical Research unit engages in the analytical method development, validation, physiochemical characterization and stability studies.
Company Coordinates stock-summary
Company Details
Dar Al Dawa Dvlpmnt & Instmnt Co Bldg, Wadi Saqrah Street, Al Rabia Area, P.O.Box 9364, AMMAN None : 11191
stock-summary
Tel: 962 6 5727132
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Abdul Rahim Jardaneh
Chairman of the Board
Ousama Yaish
Vice Chairman of the Board
Abdul Rahman Al Ghoul
Deputy General Manager - Operations, Member of the Board, representing Dar Al Dawa Company
Amer Al Khatib
General Manager, Member of the Board, representing Dar Al Dawa Company
Muannas Al Madani
Member of the Board, representing Abu Jaber Bros. Co.
Mondher Al Nabulsi
Member of the Board
Akram Jarab
Member of the Board
Dureid Jarab
General Manager, Member of the Board, representing Dar Al Dawa Company
Lina Jardaneh
Member of the Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JOD 56 Million (Small Cap)

stock-summary
P/E

9.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.51

stock-summary
Return on Equity

7.25%

stock-summary
Price to Book

0.94